The generation and characterisation of antagonist RNA aptamers to MCP-1  by Rhodes, Andrew et al.
The generation and characterisation of antagonist RNA aptamers to
MCP-1
Andrew Rhodesa;*, Nick Smithersd, Trevor Chapmanb, Sarah Parsonsc, Stephen Reesa
aMolecular Discovery Department, Glaxo Wellcome Research and Development, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK
bMolecular Recognition Department, Glaxo Wellcome Research and Development, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK
cIn vitro Pharmacology Department, Glaxo Wellcome Research and Development, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK
dMolecular Pharmacology Department, Glaxo Wellcome Research and Development, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK
Received 19 February 2001; revised 4 September 2001; accepted 5 September 2001
First published online 17 September 2001
Edited by Takashi Gojobori
Abstract Monocyte chemoattractant protein-1 (MCP-1) has
been implicated as a powerful pro-inflammatory mediator and
may represent a potentially important, therapeutic opportunity
for treatment of inflammatory disease and atherosclerosis. To
further investigate the role of MCP-1 in inflammatory disorders
we have isolated a series of RNA aptamers that bind specifically
to mouse MCP-1. The highest affinity aptamers, designated
ADR7 and ADR22, have been functionally characterised in vitro
and in cell based assays. ADR7 and ADR22 have an affinity of
180 pM and 370 pM respectively for mouse MCP-1, they can
antagonise MCP-1 binding to heparin and specifically antag-
onise MCP-1 induced chemotaxis in a cell based assay. An
interesting feature of ADR22 but not ADR7 is that it is capable
of antagonising the function of human MCP-1, demonstrating
the high level of specificity of these aptamers and that the
aptamers recognise MCP-1 in different ways. The aptamers may
be used as a tool to further investigate the role of MCP-1 in
inflammatory disorders and may also have a role as a therapeutic
agent. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Monocyte chemoattractant protein-1 (MCP-1), a L/CC che-
mokine, is responsible for the recruitment of monocytes,
T-cells, eosinophils and NK cells. Chemokine family members
are 8^10 kDa basic heparin binding proteins that are related
in both primary structure and by the position of four cysteine
residues. MCP-1 is suspected as being involved in a number of
in£ammatory disease states [1]. In£ammation in a number of
animal models including lung granuloma [2], lipopolysaccha-
ride induced death [3], glomerulonephritis [4], delayed type
hypersensitivity in the skin [5] and arthritis in mice [6] can
be reduced using neutralising antibodies. MCP-1 has been
shown to be elevated in the in£amed synovium of rheumatoid
arthritis patients and can be reduced upon treatment with
anti-arthritic drugs [7,8]. MCP-1 is elevated in asthmatic pa-
tients and there is a correlation between severity of symptoms
and level of MCP-1 [9,10]. High levels of MCP-1 are also
found in atherosclerotic lesions of humans and cholesterol
fed rabbits [11,12]. The above observations and mouse knock-
outs of either MCP-1 or its receptor CCR2 [13,14] demon-
strate that a reduction of MCP-1 activity may be bene¢cial in
treating many in£ammatory diseases and atherosclerosis.
The systematic evolution of ligands by exponential enrich-
ment (SELEX) procedure is a protocol in which single
stranded oligonucleotides are selected from vast libraries of
sequences, based on binding a⁄nity at a target protein or
other molecule [15^17]. The SELEX procedure is usually ini-
tiated with an RNA or DNA library consisting of some 1014^
1015 random oligonucleotide sequences. In a fully randomised
oligonucleotide library, each molecule will exhibit a unique
tertiary structure which will be dependent on the nucleotide
sequence of that molecule. The binding a⁄nity of the oligo-
nucleotide for the target protein will be determined by the ¢t
between moieties on the surface of the oligonucleotide and
epitopes on the target protein. As a consequence of starting
from a library of vast diversity it is often possible to identify
aptamers of nM or sub-nM a⁄nity for the target protein and
with selectivity for that target protein over other proteins with
a high degree of structural homology [18]. Using SELEX
methodology RNA or DNA aptamers have been generated
to many proteins, peptides and small molecules including do-
pamine [19], substance P [20], subtilisin [21], platelet derived
growth factor [22], vascular endothelial growth factor [23],
thrombin [24] and L-selectin [25].
Aptamers have been demonstrated to have biological activ-
ity, both in vitro and in vivo. For example an RNA aptamer
to human oncostatin M (OSM) [26] was able to block OSM
induced signalling in a variety of cell based assays and OSM,
receptor binding in in vitro assays. In a second example high
a⁄nity DNA aptamers have been raised against platelet de-
rived growth factor (PDGF) and used to investigate the role
of PDGF in renal disease [27]. The modi¢ed aptamer was
evaluated in a rat mesangioproliferative glomerulonephritis
model. The aptamer lead to 95% reduction in proliferating
mesangial cells and a 78% reduction in mitotic activity within
the glomerular.
In view of the recent advances in SELEX methodology and
numerous reports demonstrating the successful generation of
aptamers against proteins we decided to use the SELEX pro-
cedure to generate RNA aptamers to MCP-1. We report the
isolation of a series of RNA aptamers with high binding af-
¢nity for human and mouse MCP-1 that act to antagonise
MCP-1 function in a number of in vitro and cell based assays.
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2. Materials and methods
2.1. SELEX
Iterative rounds of selection/ampli¢cation were performed as de-
scribed [28] except that protein was bound to magnetic beads (Dynal)
for the partition phase of the SELEX process. 2P-Fluoropyrimidine
modi¢ed RNA containing a randomised region of 40 nucleotides was
prepared by in vitro transcription from synthetic random DNA tem-
plates. Template DNA (5P-gggaggacgaugcgg-40N-ccgcatcgtcctccc-3P),
designated 40N7, was prepared on an automated solid phase synthes-
iser (Applied Biosystems) according to the manufacturer’s protocol.
For the SELEX experiment mouse MCP-1 (RpD Systems, Minne-
apolis, MN, USA) at 3 Wg/Wl was diluted to the required concentra-
tion in SCHMK bu¡er (110 mM NaCl, 1 mM MgCl2, 20 mM HEPES
pH 7.0, 1 mM CaCl2, 5 mM KCl) and incubated with 100 Wl M-450
Dynabeads (Dynal) overnight at 4‡C to allow hydrophobic bead bind-
ing. Prior to incubation with MCP-1, the Dynabeads were washed
three times (500 Wl) with 100 mM KPO4, pH 8.0, followed by one
wash (500 Wl) with SCHMK bu¡er. All washes were carried out using
a Dynal MPC-E magnetic particle concentrator. Following overnight
incubation, unbound MCP-1 was removed and beads were washed
¢ve times with 500 Wl SHT bu¡er (1USCHMK bu¡er, 0.001%
HSA, 0.05% Tween 20). The beads were resuspended in 400 Wl
1USHT bu¡er and stored for up to 14 days at 4‡C. For each SELEX
round, RNA, diluted in 50 Wl wash bu¡er, was added to beads in
individual Eppendorf tubes at the concentrations shown in Table 1.
Tubes were incubated at 37‡C for 30 min after which individual tubes
were washed six times (500 Wl each) with 1USHT bu¡er at 37‡C to
remove unbound RNA. To elute speci¢cally bound RNA 20 Wl water
was added to individual tubes and the tube heated at 95‡C for 10 min,
the water containing eluted RNA was then removed from the mag-
netic beads to a fresh tube using the magnetic particle separator.
Reverse transcription was then carried out, followed by PCR and
transcription to generate RNA for the next round of SELEX as de-
scribed previously [28].
2.2. Dissociation constant measurements
Binding assays were carried out by nitrocellulose ¢lter partitioning
as described [28].
2.3. Cloning and sequencing
Aptamer DNA was cloned using the TA cloning kit (Invitrogen) in
the plasmid pCR2.1 according to the manufacturer’s instructions.
Plasmid clones were sequenced according to a PCR sequencing pro-
tocol [29].
2.4. Construction of the CCR2 G16 stable CHO cell lines
CCR2 was cloned at Glaxo using PCR and its sequence con¢rmed
to be identical to the published cDNA sequence [30]. The CCR2 gene
was cloned in a bi-cistronic expression vector pCIN [31] that con-
ferred resistance to the antibiotic G418 and was introduced using
standard methods [31] into a CHO host cell line that expressed the
G16 G protein from a bi-cistronic vector that conferred resistance to
the antibiotic hygromycin [32].
2.5. Assay for MCP-1 binding to heparin measured by surface plasmon
resonance
Surface plasmon resonance measurements were conducted using a
Biacore 2000 instrument at 25‡C. SCHMK bu¡er (110 mM NaCl,
1 mM MgCl2, 20 mM HEPES pH 7.0, 1 mM CaCl2, 5 mM KCl) was
used as a running bu¡er and diluent in the preparation of injection
samples. Heparin was coupled to a sensor chip by injecting biotinyl-
ated heparin (prepared at Glaxo Wellcome, Stevenage, UK) across a
streptavidin coated dextran surface (SA chip) at 2 Wg/ml and a £ow
rate of 5 Wl/min until an immobilisation level of 200 response units
(RU) was achieved. The immobilised heparin surface and a control
surface were then blocked by injecting a 50 Wg/ml solution of biotin
for 8 min. Sensograms for MCP-1 binding to heparin were obtained
by injecting MCP-1 (Peprotech EC Ltd, London, UK) at 20 nM over
both surfaces and subtracting the control channel data from the hep-
arin channel data using Biaevaluation software (Biacore AB, Uppsala,
Sweden). Flow rates of 10^20 Wl/min and injection times of at least
4 min were used to obtain near equilibrium levels of binding. The
inhibitory e¡ects of adding aptamers to the MCP-1 prior to injection
were observed and the reduction in maximum binding response calcu-
lated as a percentage of that of control responses obtained before and
after the test injections. After each injection of MCP-1 the surfaces of
the Biacore chip were regenerated with a 2 min pulse of NaCl at 1 M
concentration.
2.6. Fluorometric imaging plate reader (FLIPR) assays
All experimental steps were conducted at 37‡C unless stated other-
wise. The stable Chinese hamster ovary (CHO) human CCR2 cell line
was maintained in DMEM F-12 medium supplemented with 10%
foetal calf serum, 2 mM L-glutamine and 1 mg/ml G418. A microtitre
plate based Ca2 mobilisation FLIPR assay [33,34] was used for the
functional characterisation of the CHO hCCR2. Cells were plated at a
density of 2U105 cells/ml into black 96-well viewplates (Packard Bio-
sciences) 24 h prior to the assay. The following day the cells were
washed once with 100 Wl of FLIPR medium (10 mM HEPES, 10 mM
glucose, 3 mM probenecid, 145 mM NaCl, 5 mM KCl, 2 mM CaCl2,
1 mM MgCl2) and 200 Wl of 1 WM Fluo 4AM (Molecular Probes) in
FLIPR bu¡er was added to the cells. Following 1 h incubation (37‡C,
5% CO2), the cells were washed twice with the same bu¡er without
dye and 180 Wl of bu¡er added to each well. 10 min later, 20 Wl of 30
nM MCP-1 or MCP-1 plus aptamer was added. Plates were read
every 1 s for 1 min on a FLIPR (Molecular Devices, Sunnyvale,
CA, USA), with the agonist added at 10 s. Concentration^response
curves or single agonist responses were generated by calculating peak
£uorescence counts above background. For agonist responses to
MCP-1 in the presence/absence of aptamer, agonist was incubated
with aptamer/bu¡er for 30 min prior to addition to the cells. pEC50
values (negative log of the concentration of agonist producing 50% of
the maximal responses) were determined by ¢tting data using a four-
parameter logistic equation.
2.7. THP-1 transwell migration assay
Cells of the myelomonocytic line THP-1 (European Collection of
Cell Cultures, Wiltshire, UK) were maintained in RPMI 1640, sup-
plemented with 10% foetal bovine serum, at a density between 2U105
and 1U106 per ml. The assays were carried out in 96-well chemotaxis
chambers ¢tted with a 5 Wm pore polycarbonate ¢lter (PVP free Che-
moTX, Neuroprobe). Aptamer and chemoattractant were pre-incu-
bated for 20 min at room temperature in SCHMK bu¡er, 32 Wl of
either bu¡er alone, chemoattractant or both aptamer and chemoat-
tractant was added to each well. The ¢lter was aligned with the pegs
on the plate and placed over the wells. 50 Wl of THP-1 cells, resus-
pended in maintenance medium at a concentration of 2U106 cells/ml
was placed on top of the ¢lter above each well. The chemotaxis plate
was then incubated for 2 h at 37‡C in a humidi¢ed atmosphere of 5%
CO2.
After incubation, cells remaining on top of the ¢lter were removed
gently with a pipette and replaced with 50 Wl of 20 mM EDTA in PBS
and incubated for 10 min at room temperature. The ¢lter was care-
fully removed and 4 Wl of Calcein AM (Molecular Probes, Leiden,
The Netherlands) at a concentration of 42 Wg/ml in PBS was added to
each well. The plate was incubated for a further 20 min at 37‡C. Cell
associated £uorescence was measured in a Wallac Victor 1420 Multi-
label Counter (Perkin-Elmer, Cambridge, UK) using 485 nm excita-
tion and 535 nm emission wavelengths. A chemotaxis index was cal-
culated by dividing the £uorescence of cells migrating towards
chemoattractant by the £uorescence of cells migrating towards bu¡er
alone. Each point represents the mean and standard deviation of four
replicate wells.
3. Results
Mouse MCP-1 was chosen for aptamer generation as it was
hoped that generated aptamers could be applied in mouse
models of disease. Mouse MCP-1 expressed and puri¢ed
from E. coli was purchased from RpD Systems. To generate
high a⁄nity RNA ligands to mouse MCP-1 six iterative
rounds of SELEX were performed using the conditions de-
scribed in Table 1. To ensure the isolation of high a⁄nity
aptamers the stringency of the SELEX was increased in later
rounds by reducing the amount of protein in the experiment
[28]. The binding a⁄nity of RNA pools for the starting pro-
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tein was assessed after ¢ve and six rounds of SELEX. The
fully randomised starting pool of RNA did not bind signi¢-
cantly to mouse MCP-1 at any concentration tested up to 100
nM. The apparent a⁄nity dissociation constant (Kd) of the
RNA pool for mouse MCP-1 was 4 nM after ¢ve rounds of
selection, and was 9 nM after six rounds of selection. As there
was no signi¢cant change in a⁄nity the SELEX was assumed
to have reached completion. The round 6 pool was cloned and
60 individual aptamer clones were sequenced. The sequence
from these clones was aligned using the Clustal software pack-
age of the GCG suite of molecular biology programmes (Fig.
1). Four large and four small sequence families were identi¢ed
along with a number of orphan sequences that were only
represented once in the ¢nal pool. To characterise individual
aptamers, RNA was made from representative clones of each
sequence family and each orphan by in vitro transcription and
the binding a⁄nity for mouse MCP-1 determined (Fig. 1).
With the exception of one orphan (ADR45) all sequences
bound mouse MCP-1 with an a⁄nity of less than 20 nM.
The binding curves for the two highest a⁄nity aptamers
(ADR7 and ADR22) and for random sequence RNA are
Table 1
Protein/RNA amounts used during each round of the SELEX ex-
periment







Fig. 1. Sequence of aptamer clones. Only the 40N random region of each clone is illustrated. Sequences were aligned using the Clustal align-
ment programme from the GCG suit of molecular biology programmes. The equilibrium dissociation constant (Kd) of representative sequence
groups is shown in the right hand column.
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shown in Fig. 2a. ADR7 and ADR22 bound with a⁄nities of
180 pM and 370 pM respectively. This represents an improve-
ment in a⁄nity of at least 1000-fold over random RNA for
the best aptamer clone. The a⁄nity of ADR7 and ADR22
aptamer clones for human MCP-1 was then measured (Fig.
2b). The a⁄nity of these aptamers for human MCP-1 is sim-
ilar to that of random RNA for human MCP-1 (100 nM). To
determine if the high a⁄nity aptamers generated in this study
were capable of functionally antagonising MCP-1, the ability
of the aptamers to block the binding of MCP-1 to heparin
was measured using a Biacore assay (Fig. 3). MCP-1 binding
to heparin on the cell surface is thought to be an important
initial step in the binding of MCP-1 to the receptor. It can be
seen that both ADR22 and ADR7 functionally antagonise the
binding of mouse MCP-1 to heparin down to a concentration
equivalent to the concentration of MCP-1 injected (20 nM),
indicating a high a⁄nity interaction. ADR22 but not ADR7
also functionally antagonises the binding of human MCP-1 to
heparin, however ADR22 shows a lower level of potency
against human MCP-1 compared to mouse MCP-1, to which
it was raised. The control aptamer (ADR147) is a sequence
unrelated to the aptamer sequences evolved against MCP-1
and shows no activity in either assay. A common feature of
RNA aptamers is the ability to distinguish between closely
related proteins, thus the reduced potency against human
MCP-1 is not surprising.
The ability of ADR7 and ADR22 to antagonise human
MCP-1 signalling in a CHO cell line was tested (Fig. 4). Cal-
cium mobilisation within CHO cells, genetically engineered to
express stably both human CCR2 and the human G protein
G16, was measured by £uorescence intensity plate reader
(FLIPR) in response to human MCP-1. The results show
that ADR22 but not ADR7 or ADR147 can block human
MCP-1 signalling in a dose dependent fashion. The EC50 of
ADR22 in this assay is low (164 nM) and this is consistent
with the decreased e⁄cacy of ADR22 in the human MCP-1
heparin binding assay. Unfortunately, a cell line expressing
mouse CCR2 was not available for testing. It would however
be predicted from the above results that both ADR7 and
ADR22 would show e⁄cacy in a FLIPR assay using such a
cell line.
Fig. 2. Speci¢city of aptamer binding. Binding was carried out as
described in Section 2. a: Binding of ADR7 (R), ADR22 (F) and
random RNA (b) to mouse MCP-1. b: Binding of ADR7 (R),
ADR22 (F) and random RNA (b) to human MCP-1.
Fig. 3. Aptamer inhibition of heparin binding. Binding measure-
ments were carried out by surface plasmon resonance using a Bia-
core 2000 instrument at 25‡C. a: Inhibition of mouse MCP-1 bind-
ing to heparin by ADR7 (R), ADR22 (8) and random RNA (F).
b: Inhibition of human MCP-1 binding to heparin by ADR7 (R),
ADR22 (8) and random RNA (F).
Fig. 4. E¡ect of aptamers on human MCP-1 signalling. Calcium
mobilisation within CHO cells genetically engineered to stably ex-
press both human CCR2 and the human G protein G16, was mea-
sured by £uorescence intensity plate reader (FLIPR) in response to
human MCP-1 in the presence of ADR7 (R), ADR22 (8) and
ADR147 control (F).
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Finally the ability of ADR7 and ADR22 to antagonise
mouse MCP-1 induced chemotaxis of the myelomonocytic
cell line, THP-1, was tested. In this assay both ADR7 and
ADR22, but not the control aptamer, ADR147, blocked
mouse MCP-1 induced chemotaxis with a Ki of 3.5 nM and
14 nM respectively (Fig. 5). None of the aptamers were able
to block human MCP-1 induced chemotaxis (results not
shown), this is perhaps not surprising given the much reduced
a⁄nity and potency of the aptamers against human MCP-1.
4. Discussion
The elucidation of the role of a protein in both normal
physiology and in disease states requires the generation of
speci¢c tools that are capable of regulating the activity of
that target protein. A number of methods are available to
do this including transgenic animals and antisense RNA. To
complement these technologies, techniques have been devel-
oped that allow the generation of speci¢c nucleotide aptamers
to target proteins. In this manuscript we have used SELEX
methodology to generate high a⁄nity RNA aptamers to
mouse MCP-1 that inhibit MCP-1 activity in vitro and in
cell based assays. Following six rounds of SELEX an im-
provement in RNA a⁄nity of over 1000-fold for mouse
MCP-1 was achieved. As is often seen in a SELEX experiment
a large variation in the a⁄nities of aptamer clones selected
from the round 6 SELEX pool was observed (180 pM to
s 100 nM). Surprisingly some clones that are very prevalent
in the ¢nal RNA pool (e.g. ADR6) have amongst the lowest
a⁄nity for MCP-1. Although the primary force on aptamer
selection is a⁄nity for MCP-1, a number of other factors may
explain this observation. Firstly the e⁄ciency of transcription
of a particular aptamer sequence by T7 RNA polymerase will
in£uence its prevalence in the pool and secondly some clones
may recognise epitopes on MCP-1 that change upon hydro-
phobic adsorption to the magnetic bead surface. The larger
families of evolved aptamer sequence contain clones that dif-
fer in only one or two residues. It is likely that these have been
generated through PCR mutation during the SELEX process
resulting in a sequence that still binds MCP-1, rather than
selection of highly homologous independent sequences from
the starting library.
The speci¢city of the aptamer sequences is demonstrated by
the observation that the a⁄nity of ADR7 and ADR22 for
human MCP-1 is about a 1000-fold lower than that for mu-
rine MCP-1. In fact there is little di¡erence between the a⁄n-
ities of these aptamers and random RNA for human MCP-1.
Murine and human MCP-1 have 56% amino acid sequence
identity but mouse MCP-1 has an extra 53 amino acids in its
C-terminal portion. Both ADR7 and ADR22 can antagonise
murine MCP-1 function but only ADR22 can antagonise hu-
man MCP-1 function, although its potency is signi¢cantly
lower than for murine MCP-1. The functional data are sup-
ported by the binding data and would suggest that ADR22
can bind speci¢cally to human MCP-1 although its a⁄nity is
much lower than for murine MCP-1, it is likely that ADR7
binds to human MCP-1 in a non-speci¢c manner possibly due
to a charge e¡ect. These results would also suggest that the
MCP-1 binding site of ADR22 is di¡erent to that of ADR7.
It is likely that ADR7 and ADR22 can be truncated in
length to facilitate solid phase synthesis [26] and that a sub-
stantial number of the purine residues could be substituted
with 2P O-methyl purine to further increase stability [26].
Once an aptamer has been truncated and maximally stabilised
it is possible to make additions to the 5P end to aid use of the
aptamer in vivo. 5P modi¢cations could include addition of
polyethylene glycol to decrease plasma clearance in vivo [35]
or £uorescein or biotin for use in diagnostic applications [36].
The conjugation of a Tc99m chelating cage to ADR7 or
ADR22 may enable the in vivo imaging of MCP-1 in in£am-
matory states [37].
ADR7 and ADR22 represent highly potent and selective
functional antagonist of murine MCP-1. The aptamers gener-
ated in this study may be used to further probe the role of
MCP-1 in normal physiology and diseased states such as
rheumatoid arthritis. In addition to their use as validation
tools, the aptamer can also be developed as a diagnostic agent
and may be useful as a therapeutic molecule in its own right.
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